Atnaujinkite slapukų nuostatas

Design and Development of Novel Drugs and Vaccines: Principles and Protocols [Minkštas viršelis]

Edited by (Assistant Professor, Department of Biotechnology, Central University of Rajasthan, India), Edited by (UGC Assistant Professor, Central University of Rajasthan, Rajasthan, India)
  • Formatas: Paperback / softback, 308 pages, aukštis x plotis: 229x152 mm, weight: 450 g, 60 illustrations (30 in full color); Illustrations
  • Išleidimo metai: 22-Jan-2021
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128214716
  • ISBN-13: 9780128214718
Kitos knygos pagal šią temą:
Design and Development of Novel Drugs and Vaccines: Principles and ProtocolsDidesnis paveikslėlis
  • Formatas: Paperback / softback, 308 pages, aukštis x plotis: 229x152 mm, weight: 450 g, 60 illustrations (30 in full color); Illustrations
  • Išleidimo metai: 22-Jan-2021
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128214716
  • ISBN-13: 9780128214718
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780128214718.html
Raktažodžiai:
The Design and Development of Novel Drugs and Vaccines: Principles and Protocols presents both in silico methods and experimental protocols for vaccine and drug design and development, critically reviewing the most current research and emphasizing approaches and technologies that accelerate and lower the cost of product development. Sections review the technologies and approaches used to identify, characterize and establish a protein as a new drug and vaccine target, cover several molecular methods for in vitro studies of the desired target, and present various physiological parameters for in vivo studies. The book includes preclinical trials and research, along with information on FDA approval.
  • Covers both in silico methods and experimental protocols for vaccine and drug development in a single, accessible volume
  • Offers a holistic accounting of how developments in bioinformatics and large experimental datasets can be used in the development of vaccines and drugs
  • Shows researchers the entire gamut of current therapies, ranging from computational inputs to animal studies
  • Reviews the most current, cutting-edge research available on vaccine and drug design and development

Recenzijos

"I have read other books on clinical research, but none with the level of detail and particular focus on drug design (the computational drug design sections) that this one has. This book is very detailed-oriented from that standpoint, and it can certainly serve as a useful tool for those developing vaccines." --© Doodys Review Service, 2021, Patrick J Scoble, PharmD(PJS Pharma Consulting LLC), reviewer, expert opinion

Contributors xv
Preface xvii
Part A Computational drug design
1 Introduction of structural bioinformatics with respect to drug discovery
Hemant Arya
Mohane Selvaraj Coumar
Tarun Kumar Bhatt
1 Overview
3(8)
1.1 Drug discovery
3(2)
1.2 Structural bioinformatics (SB)
5(2)
Frequently asked questions (FAQs)
7(1)
References
7(4)
2 Target identification and validation
Hemant Arya
Mohane Selvaraj Coumar
1 Overview
11(2)
2 Steps involved in in silico target identification
13(8)
Frequently asked questions (FAQs)
19(1)
References
19(2)
3 Retrieval of compounds
Hemant Arya
Mohane Selvaraj Coumar
Tarun Kumar Bhatt
1 Overview
21(10)
1.1 Natural products
21(1)
1.2 Literature/chemical libraries
21(1)
1.3 Computational chemistry
22(1)
1.4 Steps involved in lead identification
23(5)
Frequently asked questions (FAQs)
28(1)
References
28(3)
4 Lead identification and optimization
Hemant Arya
Mohane Selvaraj Coumar
1 Overview
31(1)
2 Lead identification
31(1)
2.1 Virtual screening
31(1)
3 Lead optimization
32(4)
3.1 Computer-aided drug design (CADD)
32(1)
3.2 Molecular modeling
33(1)
3.3 Structure-based drug design (SBDD)
33(1)
3.4 Ligand-based drug design (LBDD)
34(2)
4 Modeller installation
36(5)
4.1 Steps involved in homology modeling using Modeller software
36(4)
4.2 Steps involved in homology modeling using I-TASSER online tool
40(1)
5 WHAT IF
41(1)
6 Steps involved in molecular docking
41(1)
7 AutoDock tool installation
42(15)
7.1 Steps involved in molecular docking using AutoDock tool
42(15)
8 Pharmacophore modeling using BRUSELAS
57(8)
8.1 Steps involved in pharmacophore modeling
58(3)
Frequently asked questions (FAQs)
61(1)
References
61(4)
5 Molecular dynamics simulations
Hemant Arya
Tarun Kumar Bhatt
1 Overview
65(1)
2 Gromacs installation
66(1)
3 Steps involved in molecular dynamics simulation of protein using Gromacs software
67(9)
4 Molecular dynamics simulation result analysis
76(9)
Frequently asked questions (FAQs)
80(1)
References
80(5)
Part B Computational vaccine design
6 An overview of vaccine design
Hemant Arya
Tarun Kumar Bhatt
1 Overview
85(1)
2 Key features of a potential vaccine
85(1)
3 Components of an ideal vaccine
86(1)
4 Role of bioinformatics in vaccine design
87(1)
5 An ideal vaccine design process
87(6)
5.1 Potential vaccine target identification
88(1)
5.2 B and T cell epitope prediction
88(1)
5.3 Linker and adjuvant selection
88(1)
5.4 Construct design and antigenicity/allergenicity prediction
88(1)
5.5 Structure prediction, protein-protein interactions and stability analysis
89(1)
5.6 Construct synthesis and cloning
89(1)
5.7 Expression, purification of the construct and biological assay
89(1)
Frequently asked questions (FAQs)
89(1)
Acknowledgments
90(1)
References
90(3)
7 Key steps in the selection of vaccine targets
Hemant Arya
1 Overview
93(1)
2 Vaxigen
94(3)
Frequently asked questions (FAQs)
94(1)
Acknowledgments
95(1)
References
95(2)
8 Epitope prediction and selection of linkers and adjuvant
Hemant Arya
1 Overview
97(12)
1.1 Epitope
97(1)
1.2 B-cell epitope prediction
98(1)
1.3 T-cell epitope prediction
98(1)
1.4 Linkers
99(1)
1.5 Adjuvant
99(1)
1.6 B-cell epitope prediction
100(2)
1.7 Steps involved in T-cell epitope prediction using IEDB
102(3)
Frequently asked questions (FAQs)
105(1)
Acknowledgments
106(1)
References
106(3)
9 Design of vaccine constructs
Hemant Arya
Tarun Kumar Bhatt
1 Overview
109(12)
1.1 Vaccine construct
109(1)
1.2 Antigenicity, allergenicity, toxicity, solubility and stability prediction
110(1)
1.3 Protocols
111(6)
Frequently asked questions (FAQs)
117(1)
Acknowledgments
118(1)
References
118(3)
10 In silico validation through protein-protein docking
Hemant Arya
1 Overview
121(14)
1.1 Protein-protein., interaction
121(1)
1.2 Molecular dynamics of the protein-protein complex
122(1)
1.3 Steps involved in protein-protein interaction (PPI) using the HADDOCK server
122(8)
Frequently asked questions (FAQs)
130(1)
Acknowledgments
131(1)
References
131(4)
Part C In vitro study
11 Molecular cloning
Praveen Rai
Hemant Arya
1 Overview
135(1)
1.1 Molecular cloning
135(1)
1.2 Component required for cloning
135(1)
1.3 Types of cloning
136(1)
2 PCR (polymerase chain reaction)
136(3)
3 Type of molecular cloning
139(7)
3.1 Restriction enzyme cloning
139(1)
3.2 Vectors preparation
140(4)
3.3 TA cloning
144(2)
4 Transformation
146(19)
4.1 Bacterial competent cell preparation and transformation
146(1)
4.2 Transformation
147(1)
4.3 Yeast cell preparation and transformation
147(3)
4.4 Transfection
150(8)
4.5 Insect cell transfection
158(2)
Frequently asked questions (FAQs)
160(1)
References
161(1)
Further Reading
162(3)
12 Protein expression
Praveen Rai
Diwakar Kumar
1 Protein expression
165(16)
1.1 Key features of the Prokaryotic vs. Eukaryotic translation machinery
165(1)
1.2 E. coli-based protein expression
165(10)
1.3 Yeast expression system
175(2)
1.4 Mammalian cell line expression
177(2)
Frequently asked questions (FAQs)
179(1)
References
180(1)
13 Protein purification and desalting
Praveen Rai
Hemant Arya
Diwakar Kumar
1 Overview
181(2)
1.1 Protein purification
181(2)
2 Types of protein purification
183(20)
2.1 Affinity chromatography (AC)
183(7)
2.2 Ion exchange chromatography
190(2)
2.3 Gel filtration chromatography
192(2)
2.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
194(3)
2.5 Western blot
197(2)
Frequently asked questions (FAQs)
199(1)
References
200(3)
14 Biological assay
Praveen Rai
Sujeet Singh
Surendra Nimesh
1 Overview
203(8)
1.1 Biological assay
203(6)
Frequently asked questions (FAQs)
209(1)
References
210(1)
15 Biophysical methods
Praveen Rai
Sujeet Singh
Surendra Nimesh
1 Biophysical assay/methods
211(14)
1.1 Crystallography
211(3)
1.2 Surface plasmon resonance (SPR)
214(4)
1.3 Circular dichroism (CD)
218(2)
Frequently asked questions (FAQs)
220(1)
References
220(5)
Part D In vivo study
16 Outline of animal study for lead/vaccine testing
Aparna Satapathy
Surendra Nimesh
Overview
225(1)
1 Selection of animal model
226(1)
1.1 HIV
226(1)
1.2 Zika virus
226(1)
1.3 Chikungunya virus
226(1)
1.4 Tuberculosis
226(1)
1.5 Malaria
226(1)
1.6 Leishmaniasis
227(1)
2 Ethical guidelines
227(1)
3 Animal profile
228(1)
4 Standard dose selection
228(2)
5 Mode of administration
230(1)
6 Experimental group
230(3)
Frequently asked questions (FAQs)
231(1)
References
231(2)
17 Evaluation of immunogenicity of vaccine candidates
Aparna Satapathy
Tarun Kumar Bhatt
1 Overview
233(6)
1.1 ELISA assays for quantification of antibody concentration
233(1)
1.2 Determination of T-cell immune response from mice
234(1)
1.3 Detection of cytokine profiling from mice
235(1)
1.4 Parasite inhibition assay for Plasmodium falciparum
236(1)
Frequently asked questions (FAQs)
236(1)
References
237(2)
18 In-vitro evaluation of lead molecule
Aparna Satapathy
Tarun Kumar Bhatt
1 Overview
239(8)
1.1 Microscopy based parasite count
239(3)
1.2 PCR based parasite count
242(1)
1.3 Flow cytometry method for parasite count
243(1)
Frequently asked questions (FAQs)
244(1)
References
245(2)
19 Medical physiological parameter for lead/vaccine testing
Aparna Satapathy
Surendra Nimesh
1 Overview
247(16)
1.1 Biochemical indices
248(3)
1.2 Serum parameters
251(2)
1.3 Hematological indices
253(1)
1.4 Antioxidant parameters
254(4)
Frequently asked questions (FAQs)
258(1)
References
258(5)
Part E Clinical trials and FDA approval
20 Brief introduction of clinical research and trials
Hemant Arya
Mohane Selvaraj Coumar
Tarun Kumar Bhatt
1 Overview
263(4)
Frequently asked questions (FAQs)
265(1)
References
265(2)
21 An overview of IND, NDA, approval agencies and FDA post-marketing surveillance
Hemant Arya
Surendra Nimesh
1 Overview
267(1)
2 Investigational new drug (IND)
268(1)
3 New drug application (NDA)
269(2)
4 FDA post-marketing safety monitoring
271(4)
Frequently asked questions (FAQs)
272(1)
References
272(3)
22 Introduction of intellectual property rights
Hemant Arya
Tarun Kumar Bhatt
1 Overview
275(3)
1.1 Copyrights
275(1)
1.2 Trademarks and service mark
276(1)
1.3 Trade secrets
276(1)
1.4 Geographical indication (CI)
277(1)
1.5 Traditional knowledge
277(1)
1.6 Patents
278(1)
2 How to fill the patent application in the US and India?
278(5)
2.1 Patent application filing in India
278(1)
2.2 Patent application filing in the US
279(1)
Frequently asked questions (FAQs)
280(1)
References
281(2)
Index 283
Tarun Kumar Bhatt is an Assistant Professor in the Department of Biotechnology, at the Central University of Rajasthan, India. He received his PhD from the International Centre for Genetic Engineering and Biotechnology, New Delhi and gained post-doctoral experience at the Scripps Research Institute in San Diego, California. He has published over 25 articles and has extensive experience researching drug and vaccine development. Surendra Nimesh, UGC Assistant Professor at Central University of Rajasthan, Rajasthan, India. Surendra received his M.S. in Biomedical Science from the Dr. B.R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi. He completed his PhD. In Nanotechnology at the Institute of Genomics and Integrative Biology (CSIR), Delhi. After completing his postdoctoral studies at the Ecole Polyetchnique of Montreal, Surendra joined the Clinical Research Institute of Montreal (IRCM), Canada as Postdoctoral Fellow. After completing his commitment at IRCM, he joined McGill University for short time. He also worked as NSERC visiting fellow at Health Canada, Canada. His research interests include nanoparticles-mediated gene, siRNA and drug delivery.